Experience

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85 billion…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €3.6 billion aggregate principal amount of senior notes in three…

Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised the joint book-running managers in connection with a $100.1 million SEC-registered offering of 3,850,000 ordinary shares of Theravance Biopharma, Inc. The ordinary…

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $650 million aggregate principal amount of 1.750% notes due 2022 and $850 million aggregate…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public offering by iRhythm Technologies, Inc. iRhythm sold 7,238,235 shares…

Davis Polk advised Advanced Accelerator Applications S.A. on its approximately $150 million SEC-registered follow-on offering of American Depositary Shares representing its ordinary shares…

Davis Polk advised the joint book-running managers in connection with the $60 million follow-on offering of 4,898,000 shares of common stock of Versartis, Inc. at $12.25 per share. The…

Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…